| Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype |
|
Blood |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
| Secondary Myelodysplastic Syndrome and Leukemia in Acquired Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria |
|
Blood |
Aplastic Anemia, Myelodysplastic Syndromes (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| The landscape of disease: mapping aplastic anemia |
|
Blood |
Aplastic Anemia |
| Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| Reprogramming identifies functionally distinct stages of clonal evolution in myelodysplastic syndromes |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| Genetics of Progression From MDS to Secondary Leukemia |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| Cost-effectiveness of iptacopan for paroxysmal nocturnal hemoglobinuria |
|
Blood |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Clinical decision‐making and treatment of myelodysplastic syndromes |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| Eltrombopag for refractory severe aplastic anemia: dosing, duration, long term outcomes and clonal evolution |
|
Blood |
Aplastic Anemia |
